Pomalidomide
Diffuse Large B-Cell Lymphoma Of The Central Nervous System
Explore 12 assets in Diffuse Large B-Cell Lymphoma Of The Central Nervous System →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03798314CT.gov Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma | — | Completed | — | — | — |
NCT01722305CT.gov Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma Of The Central Nervous System
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pomalidomide (this asset) | Mayo Clinic | P1 | CCC · 52 |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Dexasone | National Cancer Institute (NCI) | P1 | CC |
| Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer | National Cancer Institute (NCI) | P2 | CC |
| Pegfilgrastim | National Cancer Institute (NCI) | P1 | CC |
| Ibrutinib | National Cancer Institute (NCI) | P1 | CC |
| Venetoclax | National Cancer Institute (NCI) | P1 | CC |
| Lenalidomide | National Cancer Institute (NCI) | P1 | CC |
| Rituximab | National Cancer Institute (NCI) | P1 | CC |
+4 more in the Diffuse Large B-Cell Lymphoma Of The Central Nervous System cohort
Other indications for Pomalidomide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P4 | BB · 69 |
| Myelodysplastic Syndrome | — | P2 | B · 63 |
| Primary Central Nervous System Lymphoma | — | P2 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- NivolumabNational Cancer Institute (NCI)B
- DexasoneNational Cancer Institute (NCI)CC
- Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, DimerNational Cancer Institute (NCI)CC
- PegfilgrastimNational Cancer Institute (NCI)CC
- IbrutinibNational Cancer Institute (NCI)CC
Citation
Floatz Terminal. Pomalidomide in Diffuse Large B-Cell Lymphoma Of The Central Nervous System. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pomalidomide-diffuse-large-b-cell-lymphoma-of-the-central-nervous-system
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →